PharmaVentures Advises 3Legs Resources on its Acquisition of the Immuno-Oncology Company SalvaRx Who Announced its Admission for Trading on AIM Today

OXFORD, England, March 22, 2016 /PRNewswire/ --

PharmaVentures is pleased to announce that it acted as an independent technical and commercial expert adviser to 3Legs on its Reverse Takeover of SalvaRx. 3Legs Resources is an investment company that focuses on life sciences and related technologies. 

SalvaRx is an immuno-oncology company developing novel therapeutics that stimulate the immune system to fight cancer. SalvaRx also owns over 60% of iOx Therapeutics, which is developing anti-cancer treatments based on invariant natural killer T-cells and is poised to undertake the first Phase I/II human trials.

Adrian Dawkes, Vice President, PharmaVentures said; "In the pivotal area of immuno-oncology we were pleased to be able to provide an expert assessment of the iOx technology to support 3Legs in its acquisition."

Fintan Walton, Chief Executive of PharmaVentures said: "This is the twelfth independent expert report we have provided for companies raising finance, and the third during the recent upturn in IPO activities in the UK. Expert commercial and technical insight is a key component in company acquisitions especially where public markets are involved. PharmaVentures is able to provide valuable advisory services for our clients via our deep knowledge of the pharmaceutical and biotechnology sectors."

For over 23 years, PharmaVentures has acted as advisor to over 700 pharmaceutical and biotechnology clients in transactions; covering licensing, mergers, acquisitions, divestments and joint venture activities for companies.

About PharmaVentures, Ltd

PharmaVentures is a premier transaction advisory firm; a leader in partnering, M&A deals and strategic alliances. 

An unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes them uniquely placed to support your business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

Find out more http://www.pharmaventures.com

Their services include: 

• M&A (divestments, mergers, acquisitions and strategic transactions)
• Strategy (commercialisation, deal strategy, due diligence, market entry)
• Valuation and Positioning (licensing, M&A, fund raising & expert testimonies)
• Licensing (in and out licensing)
• Expert Testimony (patent infringement, deal disagreements, taxation, determining damages)
  

Now in its 24th year, PharmaVentures is based in Oxford, UK, and employs over 20 professionals and has associates in N. America, Latin America, and Asia-Pacific.